12:00 AM
 | 
Apr 01, 2013
 |  BioCentury  |  Finance

Tecfidera cleans up

Clean label for Biogen MS drug Tecfidera translates into $3.7B market cap bump

Biogen Idec Inc. (NASDAQ:BIIB) added $3.7 billion to its market cap after FDAapproved Tecfidera dimethyl fumarate with the cleanest label among oral MS drugs.

Doctors have told BioCentury they like the safety advantage of Tecfidera (BG-12) after Phase III studies showed flushing and abdominal pain as the most common serious adverse events (see BioCentury, April 18, 2011).

Last week, FDA approved Tecfidera for adults with relapsing-remitting MS (RRMS) with a 12-page label that includes just one warning about the potential for lymphopenia. The agency recommends a complete blood count (CBC) test prior to the...

Read the full 462 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >